- FROM THE ANALYST'S COUCH
- Correction 14 November 2019
Trends in clinical development for PD-1/PD-L1 inhibitors
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Nature Reviews Drug Discovery 19, 163-164 (2020)
doi: https://doi.org/10.1038/d41573-019-00182-w
Updates & Corrections
-
Correction 14 November 2019: The legend for Figure 1 has been corrected to reflect that there are currently 9 marketed PD-1/PD-L1 inhibitors and the legend for Figure 2 has been expanded for clarity.
Supplementary Information
Competing Interests
VHL is an unpaid scientific advisor and holds equity in FX Biopharma. The other authors declare no competing interests.